BR112017017530A2 - proteínas específicas para pioverdina e pioquelina - Google Patents

proteínas específicas para pioverdina e pioquelina

Info

Publication number
BR112017017530A2
BR112017017530A2 BR112017017530-4A BR112017017530A BR112017017530A2 BR 112017017530 A2 BR112017017530 A2 BR 112017017530A2 BR 112017017530 A BR112017017530 A BR 112017017530A BR 112017017530 A2 BR112017017530 A2 BR 112017017530A2
Authority
BR
Brazil
Prior art keywords
muteins
pioverdin
present disclosure
pioqueline
compositions
Prior art date
Application number
BR112017017530-4A
Other languages
English (en)
Inventor
Corvey Carsten
Stump Heike
Kruip Jochen
Calandra Bernhard
Rey Astrid
Karst Nathalie
Mourez Michael
Fraisse Laurent
Rothe Christine
Allersdorfer Andrea
Wiedenmann Alexander
Hinner Marlon
Lunde Bradley
Jensen Kristian
Hülsmeyer Martin
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of BR112017017530A2 publication Critical patent/BR112017017530A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente descrição fornece muteínas de hngal que li-gam um membro da família de pioverdina ou pioquelina e podem ser usadas em várias aplicações incluindo aplicações farmacêuticas, por exemplo, para inibir ou reduzir o crescimento de p. aeruginosa. a presente descrição da mesma forma relaciona-se aos métodos de preparar uma ou mais muteínas de ligação à pioquelina ou pioverdina descritas aqui, bem como, composições compreendendo uma ou mais de tais muteínas. a presente descrição também refere-se às moléculas de ácido nucleico que codificam tais muteínas e aos métodos para a geração de tais muteínas e moléculas de ácido nucleico. além disso, o pedido descreve usos terapêuticos e/ou diagnósticos destas muteínas bem como composições compreendendo uma ou mais de tais muteínas.
BR112017017530-4A 2015-02-18 2016-02-16 proteínas específicas para pioverdina e pioquelina BR112017017530A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305242 2015-02-18
EP15305242.8 2015-02-18
PCT/EP2016/053226 WO2016131804A1 (en) 2015-02-18 2016-02-16 Novel proteins specific for pyoverdine and pyochelin

Publications (1)

Publication Number Publication Date
BR112017017530A2 true BR112017017530A2 (pt) 2018-04-17

Family

ID=52595246

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017017530-4A BR112017017530A2 (pt) 2015-02-18 2016-02-16 proteínas específicas para pioverdina e pioquelina

Country Status (28)

Country Link
US (8) US9884898B2 (pt)
EP (1) EP3259282A1 (pt)
JP (1) JP6843754B2 (pt)
KR (1) KR20170116158A (pt)
CN (1) CN107660211A (pt)
AR (1) AR103714A1 (pt)
AU (1) AU2016221816B2 (pt)
BR (1) BR112017017530A2 (pt)
CA (1) CA2976687A1 (pt)
CL (1) CL2017002082A1 (pt)
CO (1) CO2017009433A2 (pt)
CR (1) CR20170425A (pt)
DO (1) DOP2017000191A (pt)
EA (1) EA035824B1 (pt)
EC (1) ECSP17061751A (pt)
GT (1) GT201700184A (pt)
HK (1) HK1245293A1 (pt)
IL (1) IL254013A0 (pt)
MA (1) MA41072A1 (pt)
MX (1) MX2017010628A (pt)
PE (1) PE20171652A1 (pt)
PH (1) PH12017501473A1 (pt)
SG (1) SG11201706621SA (pt)
TN (1) TN2017000348A1 (pt)
TW (1) TW201636364A (pt)
UY (1) UY36561A (pt)
WO (1) WO2016131804A1 (pt)
ZA (1) ZA201705257B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2510357T3 (en) 2009-12-07 2016-07-18 Pieris Ag MUTEINS OF HUMAN LIPOCALIN 2 (LCN2, HNGAL) WITH AFFINITY FOR A SPECIFIC TARGET
CA2949405C (en) 2014-05-22 2023-08-01 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
CN107207574A (zh) 2015-01-28 2017-09-26 皮里斯制药有限公司 血管生成特异性的新型蛋白
EA035824B1 (ru) * 2015-02-18 2020-08-17 Пайерис Фармасьютикалс Гмбх Новые белки, специфичные к пиовердину и пиохелину
WO2016177762A1 (en) 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CN107636014B (zh) 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
HUE061108T2 (hu) 2015-05-18 2023-05-28 Pieris Pharmaceuticals Gmbh Rákellenes fúziós polipeptid
CA2982034A1 (en) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
EP3115371A1 (en) * 2015-07-07 2017-01-11 Sanofi Fusion molecules
CA3004918A1 (en) 2015-11-30 2017-06-08 Pieris Australia Pty Ltd. Novel anti-angiogenic fusion polypeptides
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CA3105554A1 (en) * 2018-07-19 2020-01-23 The Regents Of The University Of Colorado Methods, systems and compositions for the novel use of enterobactin to treat iron deficiency and related anemia
AU2020253034A1 (en) 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
PL192364B1 (pl) 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
EP1814988A2 (en) 2004-11-26 2007-08-08 Pieris AG Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
EP2313430B1 (en) 2008-06-24 2018-05-02 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
WO2011149962A1 (en) * 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
WO2014076321A1 (en) 2012-11-19 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
CN103074303A (zh) * 2012-12-27 2013-05-01 中国人民解放军第三军医大学 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用
EA035824B1 (ru) * 2015-02-18 2020-08-17 Пайерис Фармасьютикалс Гмбх Новые белки, специфичные к пиовердину и пиохелину
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules

Also Published As

Publication number Publication date
DOP2017000191A (es) 2017-09-29
CL2017002082A1 (es) 2018-04-27
PE20171652A1 (es) 2017-11-13
US10329334B2 (en) 2019-06-25
US9884898B2 (en) 2018-02-06
AU2016221816B2 (en) 2020-07-02
CA2976687A1 (en) 2016-08-25
EA201791841A1 (ru) 2018-01-31
US20180371037A1 (en) 2018-12-27
MX2017010628A (es) 2017-12-07
US10065998B2 (en) 2018-09-04
ECSP17061751A (es) 2017-10-31
PH12017501473A1 (en) 2018-01-29
US20180371038A1 (en) 2018-12-27
ZA201705257B (en) 2019-06-26
US20170267734A1 (en) 2017-09-21
MA41072A1 (fr) 2018-10-31
AR103714A1 (es) 2017-05-31
CO2017009433A2 (es) 2017-11-30
SG11201706621SA (en) 2017-09-28
US10072056B2 (en) 2018-09-11
US20180346532A1 (en) 2018-12-06
KR20170116158A (ko) 2017-10-18
US20180037618A1 (en) 2018-02-08
US10118952B2 (en) 2018-11-06
TN2017000348A1 (en) 2019-01-16
WO2016131804A1 (en) 2016-08-25
HK1245293A1 (zh) 2018-08-24
UY36561A (es) 2016-09-30
EA035824B1 (ru) 2020-08-17
JP2018506979A (ja) 2018-03-15
GT201700184A (es) 2018-10-24
US20180030101A1 (en) 2018-02-01
AU2016221816A1 (en) 2017-10-12
CN107660211A (zh) 2018-02-02
US20180037619A1 (en) 2018-02-08
US20180086799A1 (en) 2018-03-29
TW201636364A (zh) 2016-10-16
EP3259282A1 (en) 2017-12-27
IL254013A0 (en) 2017-10-31
CR20170425A (es) 2017-11-22
JP6843754B2 (ja) 2021-03-17

Similar Documents

Publication Publication Date Title
BR112017017530A2 (pt) proteínas específicas para pioverdina e pioquelina
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
CL2017000201A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112018006448A2 (pt) derivado de oxaespiro, método de preparação dos mesmos, e aplicações dos mesmos em medicamentos
BR112017015773A2 (pt) muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112016030462A2 (pt) moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo
BR112018002130A2 (pt) anticorpo de domínio único e proteínas derivadas respectivas contra um ligante de morte programada (pdl1)
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
BR112016027024A2 (pt) polipeptídeos de ligação específica e seus usos
BR112017027567A2 (pt) proteínas de fusão para inibir a angiogênese
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
BR112018014288A2 (pt) métodos e composições para o tratamento de doença neurológica
BR112016015660A2 (pt) formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg)
BR112017026292A2 (pt) muteína de lipocalina, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método de produção de muteína de lipocalina, métodos de ligação de lag-3 em pacientes, de estímulo da reação imunológica em pacientes, de indução da proliferação de linfócitos t, de interferir com a ligação de lag-3 humano e de detecção da presença de lag-3, composição farmacêutica, imunoconjugado, uso de muteína e kit analítico ou de diagnóstico
GT201800102A (es) Polipéptidos que inhiben cd4ol
BR112015030774A2 (pt) novos compostos para o tratamento de câncer
MX2015016120A (es) Moleculas de union que se adhieren al factor de complemento c2 humano y usos de los mismos.
DOP2018000001A (es) Moléculas de fusión
BR112017024714A2 (pt) métodos para preparação do fator de von willebrand modificado
BR112019008516A2 (pt) derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo
BR112015022475A2 (pt) formulações com oxidação reduzida

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25A Requested transfer of rights approved

Owner name: PIERIS PHARMACEUTICALS GMBH (DE)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2658 DE 14-12-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.